DWA
BCLI

Dorsey Wright & Associates’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Dorsey Wright & Associates’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-75
Closed -$19K – 317
2020
Q3 		$19K Sell
75
-25
-25% -$5.12K ﹤0.01% 155
2020
Q2 		$17K Buy
+100
New +$10.8K ﹤0.01% 172

Other funds holding BCLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dorsey Wright & Associates's BCLI Position: Q4 2020 in Review

Dorsey Wright & Associates sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2020, closing a stake of 75 shares — an estimated $19K sold.

Dorsey Wright & Associates first reported a position in BCLI in Q2 2020 and held it in 2 quarters. The position peaked at $19K in Q3 2020. 90 funds tracked by Wall St. Rank hold BCLI as of Q4 2020.

  • Dorsey Wright & Associates reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2020 after selling out during the quarter.
  • Dorsey Wright & Associates sold 75 BRAINSTORM CELL THERAPUTC shares in Q4 2020, an estimated $19K.
  • Dorsey Wright & Associates first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2020 and held it in 2 quarters.
  • Dorsey Wright & Associates's BRAINSTORM CELL THERAPUTC position peaked at $19K in Q3 2020.
  • 90 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2020.

Based on Dorsey Wright & Associates's 13F filing for Q4 2020, filed 28 Jan 2021.